Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety of adebrelimab injection in non-small cell lung cancer
ChiCTR2400081790Phase 4Recruiting
- Sponsor
- Eighth Medical Center of the People's Liberation Army General Hospital
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Eighth Medical Center of the People's Liberation Army General Hospital. Primary endpoint: Safety (occurrence of ≥ grade 3 adverse events). Started Mar 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400081790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081790.